期刊
CELL CYCLE
卷 9, 期 24, 页码 4788-4794出版社
TAYLOR & FRANCIS INC
DOI: 10.4161/cc.9.24.14360
关键词
cell senescence; mTOR; rapamycin; target of rapamycin; aging; diseases
类别
Although we do not know everything about aging, we now know enough to start its pharmacologic suppression using clinically approved drugs. Aging turns out to be driven by sensing-signaling pathways (such as the mTOR pathway). Given that some inhibitors of the mTOR pathway are already in clinical use, there is a unique opportunity to suppress aging, while treating and preventing diseases. By itself this will answer some burning questions in gerontology. Here I discuss a proposal, starting from retrospective clinical studies to animal and cellular models to drug screens in order to develop non-toxic and effective schedules and drug combinations for extending healthy life spans in our lifetime.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据